Published in PLoS One on September 11, 2013
Are common fragile sites merely structural domains or highly organized "functional" units susceptible to oncogenic stress? Cell Mol Life Sci (2014) 0.90
DNA secondary structure at chromosomal fragile sites in human disease. Curr Genomics (2015) 0.82
Molecular Process Producing Oncogene Fusion in Lung Cancer Cells by Illegitimate Repair of DNA Double-Strand Breaks. Biomolecules (2015) 0.77
Linking Pesticide Exposure with Pediatric Leukemia: Potential Underlying Mechanisms. Int J Mol Sci (2016) 0.77
Environmental and chemotherapeutic agents induce breakage at genes involved in leukemia-causing gene rearrangements in human hematopoietic stem/progenitor cells. Mutat Res (2015) 0.75
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A (1987) 14.25
Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol (2002) 11.79
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev (2009) 8.08
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Transcription generates positively and negatively supercoiled domains in the template. Cell (1988) 5.73
Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer (2009) 5.55
Chromosome fragile sites. Annu Rev Genet (2007) 4.95
Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell (2005) 4.91
Initiation of SV40 DNA replication in vivo: location and structure of 5' ends of DNA synthesized in the ori region. Cell (1982) 4.50
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer (2006) 3.83
Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 2.96
DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet (1984) 2.92
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol Cell (2011) 2.66
All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol (2011) 2.66
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
RET/PTC rearrangement in thyroid tumors. Endocr Pathol (2002) 2.42
Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res (1984) 2.37
Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer (2005) 2.30
Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc Natl Acad Sci U S A (2007) 2.27
Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci U S A (1998) 2.16
Topological challenges to DNA replication: conformations at the fork. Proc Natl Acad Sci U S A (2001) 2.11
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
Molecular basis for expression of common and rare fragile sites. Mol Cell Biol (2003) 1.78
Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res (2002) 1.78
Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem (1998) 1.73
Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection. Br J Cancer (1989) 1.68
Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet (1998) 1.65
R loops stimulate genetic instability of CTG.CAG repeats. Proc Natl Acad Sci U S A (2009) 1.64
A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res (2007) 1.63
Metabolism of Okazaki fragments during simian virus 40 DNA replication. J Biol Chem (1979) 1.62
An AT-rich sequence in human common fragile site FRA16D causes fork stalling and chromosome breakage in S. cerevisiae. Mol Cell (2007) 1.51
Common fragile sites. Cancer Lett (2005) 1.48
Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats. Nucleic Acids Res (2010) 1.32
Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage. J Biol Chem (1994) 1.30
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res (1985) 1.28
Replication delay along FRA7H, a common fragile site on human chromosome 7, leads to chromosomal instability. Mol Cell Biol (2000) 1.27
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab (2005) 1.24
DNA polymerase epsilon: aphidicolin inhibition and the relationship between polymerase and exonuclease activity. Biochemistry (1993) 1.24
DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta (1998) 1.20
Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics (2009) 1.17
Hypernegative supercoiling of the DNA template during transcription elongation in vitro. J Biol Chem (1994) 1.16
Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res (2007) 1.15
Functional interactions of DNA topoisomerases with a human replication origin. EMBO J (2007) 1.14
DNA instability at chromosomal fragile sites in cancer. Curr Genomics (2010) 1.11
Rare fragile sites. Cytogenet Genome Res (2003) 1.11
DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene (2010) 1.09
In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res (1989) 1.08
Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha. Mol Pharmacol (2000) 1.06
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. Nucleic Acids Res (1997) 1.05
Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res (2002) 1.04
Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer (1999) 1.04
Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene (1999) 1.02
DNA structure and the Werner protein modulate human DNA polymerase delta-dependent replication dynamics within the common fragile site FRA16D. Nucleic Acids Res (2009) 1.02
Secondary malignancies following cancer chemotherapy. Acta Oncol (1994) 0.99
Transcription-induced DNA toxicity at trinucleotide repeats: double bubble is trouble. Cell Cycle (2011) 0.97
Breakage of single-stranded DNA by eukaryotic type 1 topoisomerase occurs only at regions with the potential for base-pairing. J Mol Biol (1984) 0.96
Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg (2003) 0.93
Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha. Nucleic Acids Res (2008) 0.93
Detection of the PTC/retTPC oncogene in human thyroid cancers. Oncogene (1992) 0.92
Analysis of replication timing at the FRA10B and FRA16B fragile site loci. Chromosome Res (2000) 0.91
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma. Hum Mol Genet (1995) 0.89
Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg (1993) 0.89
Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites. DNA Repair (Amst) (2010) 0.89
Replication timing of two human common fragile sites: FRA1H and FRA2G. Cytogenet Genome Res (2008) 0.88
Comparison of the breakpoint regions of ELE1 and RET genes involved in the generation of RET/PTC3 oncogene in sporadic and in radiation-associated papillary thyroid carcinomas. Genomics (1997) 0.86
Betulinic acid and its derivatives, potent DNA topoisomerase II inhibitors, from the bark of Bischofia javanica. Chem Biodivers (2005) 0.86
Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer (1993) 0.86
Role of DNA secondary structures in fragile site breakage along human chromosome 10. Hum Mol Genet (2013) 0.85
Rational design and semisynthesis of betulinic acid analogues as potent topoisomerase inhibitors. J Nat Prod (2009) 0.82
Two breakpoint clusters at fragile site FRA3B form phased nucleosomes. Genome Res (2004) 0.79
Secondary thyroid neoplasms in pediatric cancer patients: increased risk with improved survival. J Pediatr Surg (1984) 0.78
Childhood papillary thyroid cancer as second malignancy after successful treatment of rhabdomyosarcoma. Acta Oncol (2008) 0.76
Secondary thyroid papillary carcinoma in osteosarcoma patients: report of two cases. J Korean Med Sci (2008) 0.76
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
L3MBTL1, a histone-methylation-dependent chromatin lock. Cell (2007) 3.70
MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab (2008) 3.40
Evidence of cis-acting factors in replication-mediated trinucleotide repeat instability in primate cells. Nat Genet (2002) 2.81
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol (2007) 2.75
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid (2012) 2.71
Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol (2003) 2.67
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
Thyroid nodules (≥4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg (2014) 2.40
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol (2011) 2.25
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17
Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol (2006) 2.15
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene (2005) 1.99
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol (2012) 1.90
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology (2006) 1.85
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
The functional interaction of the hepatitis C virus helicase molecules is responsible for unwinding processivity. J Biol Chem (2004) 1.76
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery (2009) 1.72
PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol (2002) 1.70
Slipped-strand DNAs formed by long (CAG)*(CTG) repeats: slipped-out repeats and slip-out junctions. Nucleic Acids Res (2002) 1.64
Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol (2003) 1.56
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab (2006) 1.39
Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol (2002) 1.33
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab (2009) 1.32
Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats. Nucleic Acids Res (2010) 1.32
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A (2014) 1.32
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Self-association of collagen triple helic peptides into higher order structures. J Biol Chem (2006) 1.30
Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J Med Chem (2005) 1.28
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res (2006) 1.27
MicroRNA expression profiles in thyroid tumors. Endocr Pathol (2009) 1.27
Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab (2005) 1.24
Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab (2012) 1.24
Molecular analysis of thyroid tumors. Endocr Pathol (2011) 1.23
RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J Clin Endocrinol Metab (2013) 1.22
Proliferative activity of human thyroid cells in various age groups and its correlation with the risk of thyroid cancer after radiation exposure. J Clin Endocrinol Metab (2006) 1.22
A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer (2011) 1.21
Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res (2010) 1.21
Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol (2013) 1.19
ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer (2013) 1.18
Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics (2009) 1.17
DNA instability at chromosomal fragile sites in cancer. Curr Genomics (2010) 1.11
MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J Clin Endocrinol Metab (2012) 1.11
Secondary structure formation and DNA instability at fragile site FRA16B. Nucleic Acids Res (2010) 1.11
Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. J Mol Diagn (2010) 1.10
Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest (2013) 1.09
Highly compacted chromatin formed in vitro reflects the dynamics of transcription activation in vivo. Mol Cell (2010) 1.08
Adaptive Accelerated Molecular Dynamics (Ad-AMD) Revealing the Molecular Plasticity of P450cam. J Phys Chem Lett (2011) 1.07
Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.06
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol (2011) 1.04
BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol (2012) 1.04
RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. Cancer (2013) 1.04
Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid (2013) 1.02
Homologous chromosomes make contact at the sites of double-strand breaks in genes in somatic G0/G1-phase human cells. Proc Natl Acad Sci U S A (2012) 1.02
Chromatin structure can strongly facilitate enhancer action over a distance. Proc Natl Acad Sci U S A (2006) 1.00
A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg (2014) 0.99
Tumor-to-tumor metastases to follicular variant of papillary thyroid carcinoma: histologic, immunohistochemical, and molecular studies of two unusual cases. Endocr Pathol (2009) 0.98
Alterations of the BRAF gene in thyroid tumors. Endocr Pathol (2005) 0.97
Diagnosis and management of differentiated thyroid cancer using molecular biology. Laryngoscope (2013) 0.97
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol (2005) 0.97
Protecting High Energy Barriers: A New Equation to Regulate Boost Energy in Accelerated Molecular Dynamics Simulations. J Chem Theory Comput (2011) 0.97
Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathol (2014) 0.96
RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii. Endocr Pathol (2010) 0.95
Suspicious ultrasound characteristics predict BRAF V600E-positive papillary thyroid carcinoma. Thyroid (2012) 0.94
Is ionizing radiation responsible for the increasing incidence of thyroid cancer? Cancer (2010) 0.93
Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration. Cancer Cytopathol (2012) 0.93
Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery (2013) 0.91
Utilization of ancillary studies in thyroid fine needle aspirates: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 0.90
Sequence dependence of kinetics and morphology of collagen model peptide self-assembly into higher order structures. Protein Sci (2008) 0.90
Effect of CAT or AGG interruptions and CpG methylation on nucleosome assembly upon trinucleotide repeats on spinocerebellar ataxia, type 1 and fragile X syndrome. J Biol Chem (2004) 0.90
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
HOOK3-RET: a novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer (2007) 0.89
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res (2004) 0.89
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis. J Clin Endocrinol Metab (2009) 0.88
MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights. J Mol Endocrinol (2014) 0.88
On the Use of Accelerated Molecular Dynamics to Enhance Configurational Sampling in Ab Initio Simulations. J Chem Theory Comput (2011) 0.88
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. Pediatr Blood Cancer (2010) 0.88
The ATTCT repeats of spinocerebellar ataxia type 10 display strong nucleosome assembly which is enhanced by repeat interruptions. Gene (2008) 0.86
Formation of carcinogenic chromosomal rearrangements in human thyroid cells after induction of double-strand DNA breaks by restriction endonucleases. Endocr Relat Cancer (2012) 0.86
PAX8/PPARγ rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid (2014) 0.86
Gene position within chromosome territories correlates with their involvement in distinct rearrangement types in thyroid cancer cells. Genes Chromosomes Cancer (2009) 0.86
Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. Eur J Cancer (2005) 0.85
RET/PTC Rearrangement--a link between Hashimoto's thyroiditis and thyroid cancer...or not. J Clin Endocrinol Metab (2006) 0.85
Role of DNA secondary structures in fragile site breakage along human chromosome 10. Hum Mol Genet (2013) 0.85
Homologous chromosomes move and rapidly initiate contact at the sites of double-strand breaks in genes in G₀-phase human cells. Cell Cycle (2013) 0.85
MicroRNA dysregulation in human thyroid cells following exposure to ionizing radiation. Thyroid (2011) 0.84
Distal loop flexibility of a regulatory domain modulates dynamics and activity of C-terminal SRC kinase (csk). PLoS Comput Biol (2013) 0.84
Use of molecular biomarkers in FNA specimens to personalize treatment for thyroid surgery. Head Neck (2012) 0.84
Friedreich's ataxia GAA.TTC duplex and GAA.GAA.TTC triplex structures exclude nucleosome assembly. J Mol Biol (2008) 0.84
The molecular dynamics of Trypanosoma brucei UDP-galactose 4'-epimerase: a drug target for African sleeping sickness. Chem Biol Drug Des (2012) 0.82